Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) CFO Daron Evans bought 40,000 shares of the stock in a transaction on Friday, June 14th. The stock was acquired at an average cost of $4.04 per share, for a total transaction of $161,600.00. Following the acquisition, the chief financial officer now directly owns 40,000 shares in the company, valued at $161,600. The transaction was disclosed in a filing with the SEC, which is available through this link.
Daron Evans also recently made the following trade(s):
- On Wednesday, May 29th, Daron Evans acquired 451 shares of Rezolute stock. The stock was acquired at an average cost of $3.50 per share, with a total value of $1,578.50.
- On Thursday, May 23rd, Daron Evans bought 58 shares of Rezolute stock. The shares were bought at an average cost of $2.85 per share, for a total transaction of $165.30.
Rezolute Stock Down 23.4 %
Shares of RZLT stock opened at $3.95 on Monday. The company has a market capitalization of $158.51 million, a P/E ratio of -3.46 and a beta of 1.31. Rezolute, Inc. has a 12-month low of $0.72 and a 12-month high of $6.10. The firm has a 50-day moving average price of $3.45 and a 200 day moving average price of $2.09.
Institutional Trading of Rezolute
Several large investors have recently made changes to their positions in the business. Federated Hermes Inc. lifted its position in Rezolute by 53.6% during the 4th quarter. Federated Hermes Inc. now owns 10,154,327 shares of the company’s stock worth $10,083,000 after buying an additional 3,544,053 shares in the last quarter. Vivo Capital LLC lifted its position in shares of Rezolute by 569.4% during the fourth quarter. Vivo Capital LLC now owns 3,242,842 shares of the company’s stock worth $3,219,000 after purchasing an additional 2,758,403 shares in the last quarter. Affinity Asset Advisors LLC bought a new stake in shares of Rezolute during the first quarter valued at approximately $4,080,000. Vanguard Group Inc. grew its stake in shares of Rezolute by 10.4% during the first quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock valued at $3,961,000 after purchasing an additional 145,700 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new position in Rezolute in the 1st quarter worth approximately $510,000. Institutional investors own 82.97% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have issued reports on RZLT. JMP Securities restated a “market outperform” rating and issued a $7.00 price target on shares of Rezolute in a research report on Thursday, April 18th. Craig Hallum initiated coverage on Rezolute in a research report on Tuesday, June 4th. They set a “buy” rating and a $14.00 target price on the stock. Jonestrading assumed coverage on Rezolute in a research note on Thursday, April 18th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research report on Wednesday, May 22nd. Finally, Maxim Group began coverage on Rezolute in a report on Tuesday, April 9th. They set a “buy” rating and a $8.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $9.67.
Check Out Our Latest Stock Report on Rezolute
Rezolute Company Profile
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Recommended Stories
- Five stocks we like better than Rezolute
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 6/10 – 6/14
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- 3 Warren Buffett Stocks to Buy Now
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.